Compare ANDE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | PHVS |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | Switzerland |
| Employees | 2137 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2005 | 2020 |
| Metric | ANDE | PHVS |
|---|---|---|
| Price | $64.15 | $33.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $86.67 | $57.68 |
| AVG Volume (30 Days) | 286.3K | ★ 594.3K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $11,008,928,000.00 | N/A |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.75 | N/A |
| P/E Ratio | $23.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $44.87 | $21.02 |
| 52 Week High | $82.11 | $43.25 |
| Indicator | ANDE | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 59.56 |
| Support Level | N/A | $33.41 |
| Resistance Level | $68.83 | $36.36 |
| Average True Range (ATR) | 2.03 | 1.27 |
| MACD | -0.11 | 0.57 |
| Stochastic Oscillator | 31.54 | 93.53 |
Andersons Inc is an agriculture and renewable fuels company. Its operations are classified into two reportable business segments: Agribusiness, which generates maximum revenue, and Renewables. The Agribusiness segment includes merchandising and managing logistics across various commodities, as well as being a manufacturer, distributor, and retailer of agricultural and related plant nutrients. The segment specializes in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. The Renewables segment mainly produces, purchases, and sells ethanol and co-products. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.